



EXPRESS MAIL LABEL NO. EF077944616US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

U.S. National Phase Application Corresponding To:

Applicants:  
USSN:  
Filed:  
Title:

Jacques Drouin, et al.  
09/319,782  
10 June 1999  
NUR-RE A RESPONSE ELEMENT WHICH  
BINDS NUR NUCLEAR RECEPTORS AND  
METHOD OF USE THEREFOR  
1636  
Konstantina Katcheves  
480848.90018

Group Art Unit:  
Examiner:  
Docket No.:

RECEIVED  
DEC 06 2001  
TECH CENTER 1600/2900

Commissioner for Patents  
Washington, D.C. 20231

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS  
FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE  
AND/OR AMINO ACID SEQUENCE DISCLOSURES

Dear Sir:

In response to a Notice to Comply under date of  
mailing of October 4, 2001, Applicants respectfully enclose:

1. A revised Sequence Listing Disk in computer  
readable form, which has been marked Drouin,  
et al.

No fees are believed to be due in connection with  
this Response. However, the Commissioner is hereby authorized  
to charge any additional fees which may be required, or credit  
any overpayment to Deposit Account No. 17-0055. A duplicate  
copy of this sheet is enclosed.

Respectfully submitted,

01 November 2001

By:

*Jean C. Baker*  
Jean C. Baker  
QUARLES & BRADY LLP  
411 East Wisconsin Avenue  
Milwaukee, WI 53202  
Reg. No.: 35,433  
(414) 277-5709  
(414) 271-3552/Fax



UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
09/319,782	04/19/00	DROUIN	480848.90018

016710  
QUARLES & BRADY LLP  
411 E. WISCONSIN AVENUE  
SUITE 2040  
MILWAUKEE WI 53202-4497

HZ12/1004

EXAMINER KATCHERES, R
--------------------------

ART UNIT 1636	PAPER NUMBER
------------------	--------------

DATE MAILED: 10/06/01

RECEIVED  
DEC 06 2001  
TECH CENTER 1600/2900

Please find below and/or attached an Office communication concerning this application of proceeding.

Commissioner of Patents and Trademarks





UNITED STATES

PATENT AND TRADEMARK OFFICE

NOV 01 2001

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, DC 20531  
www.uspto.govRECEIVED  
DEC 08 2001  
TECH CENTER

ATTORNEY DOCKET NO.

430018 90018

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION
09319782	19 APRIL 2000	DROUIN ET AL.

EXAMINER

KATCHEVES

ART UNIT	PAPER
----------	-------

1636

13

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents

The communication filed 11 May 2001 is not fully responsive to the Office communication mailed 2 February 2001 for the reason(s) set forth on the attached Notice To Comply With The Sequence Rules. The Application still fails to contain a sequence listing. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

Since the reply appears to be *bona fide* attempt to comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825), the applicant is given a TIME PERIOD of **ONE (1) MONTH** from the mailing date of this communication within which to correct the deficiency so as to comply with the sequence rules (37 CFR 1.821 - 1.825) in order to avoid abandonment of the application under 37 CFR 1.821(g). **EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 CFR 1.136(a).**

Any inquiry concerning this communication should be directed to Examiner Konstantina Katcheves, Art Unit 1636, whose telephone number is (703) 305-1999.

Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center receptionist whose telephone number is (703) 308-0196.

  
ANDREW WANG  
PRIMARY EXAMINER



# **Notice to Comply**

Application No.

09/319782

Examiner

Konstantina Katcheves

Applicant(s)

Drouin et al.

Art Unit

1636

## **NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Applicant must file the items indicated below within the time period set the Office action to which the notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☐ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☒ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other:

### **Applicant Must Provide:**

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☐ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☐ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY**

RECEIVED  
06/20/2001  
PATENT CENTER